Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.

Breast cancer research and treatment·2026
Same author

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer.

Breast cancer research and treatment·2026
Same author

Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.

Journal for immunotherapy of cancer·2026
Same author

Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study.

Breast cancer research and treatment·2026
Same author

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence.

medRxiv : the preprint server for health sciences·2026
Same author

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Related Experiment Video

Updated: Apr 26, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.8K

Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach.

Dame Idossa1, Maeve A Hennessy2, Alexis LeVee3

  • 1Division of Oncology, Department of Oncology, Mayo Clinic, Rochester, MN.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|April 24, 2026
PubMed
Summary
This summary is machine-generated.

Stage I triple-negative breast cancer (TNBC) management lacks prospective data. This review explores current and emerging systemic therapies, focusing on treatment de-escalation and biomarkers for personalized selection in early-stage TNBC.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.2K

Related Experiment Videos

Last Updated: Apr 26, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.2K

Area of Science:

  • Oncology
  • Breast Cancer Research
  • Clinical Trial Design

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype lacking standard biomarkers.
  • Current TNBC treatment guidelines often rely on data from later stages (II/III).
  • Stage I TNBC populations are underrepresented in prospective trials, limiting evidence for optimal management.

Purpose of the Study:

  • To review existing evidence for systemic therapy in stage I TNBC.
  • To focus on treatment de-escalation strategies for early-stage TNBC.
  • To identify promising biomarkers for personalized treatment selection in stage I TNBC.

Main Methods:

  • Literature review of prospective and retrospective studies.
  • Analysis of current guidelines and clinical trial data for TNBC.
  • Evaluation of emerging biomarkers and their potential clinical utility.

Main Results:

  • Limited prospective data exists for stage I TNBC outcomes and chemotherapy benefit.
  • Treatment decisions for stage I TNBC are often extrapolated from advanced stages.
  • Biomarker-driven approaches are emerging for personalized therapy selection.

Conclusions:

  • Further prospective research is needed to define optimal systemic therapy for stage I TNBC.
  • Treatment de-escalation guided by biomarkers may be feasible for select early-stage TNBC patients.
  • Personalized medicine holds promise for improving outcomes in stage I TNBC.